.png)
The Stress and Risks of PBM Audits
For pharmacies, few events are as stressful, or as disruptive, as a PBM audit. These audits often result in findings that are exaggerated, misleading, or simply inaccurate. Even minor inventory discrepancies or routine record-keeping errors can trigger steep recoupment demands and, in some cases, lead to network termination. The important point to remember is that pharmacies do not have to accept adverse audit findings at face value. Every audit finding can be appealed, and there are effective strategies to challenge improper results and significantly reduce or eliminate clawbacks based on inaccurate audit findings.
Reviewing and Rebutting Audit Findings
The appeal process begins with a careful review of the audit and/or discrepancy report. PBM auditors frequently cite technical issues, such as missing inventory records, missing patient signatures, minor inconsistencies in prescription records, or gaps in copayment documentation, as grounds for full recoupment. In many situations, these alleged deficiencies can be rebutted by submitting supplemental records, clarifying documentation, or obtaining patient attestations. A thorough, line-by-line analysis of the discrepancy report is essential to uncovering errors and mounting a strong defense.
Protecting Contractual Rights During the Appeal
Pharmacies must also be mindful of their contractual rights. PBM provider manuals set strict timelines and procedures for disputing audit results. Missing a deadline or failing to submit the required information can make it nearly impossible to overturn an adverse finding. Responding quickly, completely, and in compliance with contractual requirements is critical to protecting the pharmacy’s position and avoiding unwarranted repayment obligations.
Providing Context to Alleged Discrepancies
Moreover, providing context to certain alleged discrepancies can further strengthen a pharmacy’s defense. For example, what may appear to be a suspicious pattern, such as a high number of claim reversals, can often be explained by inventory shortages requiring reversals or by patient-driven requests, both of which are factors entirely outside the pharmacy’s control. Explaining these circumstances and supporting them with appropriate documentation can help dismantle PBM assumptions and reduce the likelihood of unfair recoupment.
The Value of Experienced Legal Counsel
Because the financial and operational stakes are so high, pharmacies benefit from working with an experienced healthcare attorney who has specific knowledge of PBM audits and appeals. A skilled PBM audit attorney can identify weaknesses in the audit findings, ensure contractual rights are preserved, and prepare formal appeals backed by legal and factual analysis. When necessary, PBM defense attorneys can also escalate matters to prevent unjust clawbacks and protect network participation.
How Health Law Alliance Can Help
At Health Law Alliance, we represent pharmacies nationwide in challenging PBM audit findings and defending against network terminations. Our attorneys understand the tactics PBMs use during audits and know how to craft effective appeals that protect pharmacies from unfair financial and operational consequences. Whether you are reviewing a recent audit report, preparing an appeal, or facing threats of network termination, contact us today to learn how we can help you challenge PBM audit findings and/or network termination notices before they cause lasting harm to your pharmacy.
MORE ARTICLES BY CATEGORY
Texas Moves to Rein in Ketamine Therapy—And Other States are Likely Next
The regulatory environment surrounding ketamine therapy is entering a new phase of maturity and enforcement. Recently, the Texas Medical Board published proposed regulations governing ketamine therapy, one of the first comprehensive regulatory frameworks in the country.
Read More >>California Hospice Fraud Crackdown: What it Means for Providers & How to Protect Your Business
California’s hospice fraud crackdown is only the beginning of what CMS and Medi-Cal regulators have claimed will be many more cases brought against hospice facilities and home health agencies. Providers who do not timely respond to a suspension or revocation may waive important rights. Act now to protect your business and reputation from governmental overreach based on data mining and other unreliable sources.
Read More >>New Executive Order Signals Faster Psychedelic Drug Approvals--and Closer DEA Scrutiny
On Saturday, April 18, President Trump signed an executive order designed to accelerate federal drug approvals for psychedelic drugs, a move experts are calling a significant win for patient access. But for ketamine providers and practices offering ketamine-assisted psychotherapy (KAP), increased coordination among regulators means increased scrutiny is inevitable. In this article, we break down what this executive order means for the future of regulatory enforcement.
Read More >>The WISeR Model: A New Era of Prior Authorization and Audit Risks for Wound Care
On January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) officially launched the Wasteful and Inappropriate Service Reduction (WISeR) Model. This initiative is not just another administrative hurdle; it is a technology-driven enforcement overhaul aimed directly at the wound care industry.
Read More >>







